The Pointy End of the NAFLD Iceberg: Cirrhosis, Portal Hypertension, and Liver Failure

Jonathon W. Schwake*, Dawn M. Torres, Stephen A. Harrison

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


This chapter discusses the progression of non-alcoholic steatohepatitis (NASH) to advanced fibrosis and cirrhosis, which occurs within the broader disease spectrum of non-alcoholic fatty liver disease (NAFLD). NASH appears to progress slowly to cirrhosis in a substantial number of patients, although the exact rate of disease progression has been difficult to predict. The leading cause of death in NASH remains vascular disease, although after progression to cirrhosis, liver-related complications become the major determinant of mortality. The occurrence of decompensated liver disease and hepatocellular carcinoma (HCC) appears to occur less frequently in NASH cirrhosis than in patients with cirrhosis due to hepatitis C, although overall mortality rates remain similar. Finally, NASH cirrhosis is expected to become the most common indication for liver transplant in future decades, with posttransplant survival in selected patients similar to that due to other common liver diseases, despite the recurrence of NAFLD in most patients.

Original languageEnglish
Title of host publicationNon-Alcoholic Fatty Liver Disease
Subtitle of host publicationA Practical Guide
Number of pages10
ISBN (Print)9780470673171
StatePublished - 8 Mar 2013
Externally publishedYes


  • Cirrhosis
  • Cryptogenic
  • Fibrosis
  • Non-alcoholic fatty liver disease (NAFLD)
  • Non-alcoholic steatohepatitis (NASH)
  • Transplant


Dive into the research topics of 'The Pointy End of the NAFLD Iceberg: Cirrhosis, Portal Hypertension, and Liver Failure'. Together they form a unique fingerprint.

Cite this